Article metrics

Original research
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

 

Online download statistics by month:

Online download statistics by month: August 2024 to October 2024

AbstractFullPdf
Aug 202411201128442
Sep 2024315315210
Oct 2024318319189
Total17531762841